Matching articles for "colchicine"
Issue 1688 · October 30, 2023
Drugs for Gout

Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint…

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):169-75 doi:10.58347/tml.2023.1688a
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Issue 1688 · October 30, 2023
Comparison Table: Some Drugs for Gout (online only)

View the Comparison Table: Some Drugs for Gout

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):e176-9 doi:10.58347/tml.2023.1688c
View the Comparison Table: Some Drugs for Gout
Issue 1686 · October 2, 2023
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention

Colchicine ( Colcrys , and others), which has been available in the US for decades for prophylaxis and treatment of gout flares and other indications in oral formulations that contain 0.6 mg of the drug, has…

Med Lett Drugs Ther. 2023 Oct 2; 65(1686):156-7 doi:10.58347/tml.2023.1686b
Colchicine ( Colcrys , and others), which has been available in the US for decades for prophylaxis and treatment of gout flares and other indications in oral formulations that contain 0.6 mg of the drug, has now been approved in 0.5-mg tablets as Lodoco (Agepha) to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple risk factors for cardiovascular disease.
Issue 1632 · September 6, 2021
Rilonacept (Arcalyst) for Recurrent Pericarditis

Rilonacept ( Arcalyst – Kiniksa), an interleukin-1 (IL-1) antagonist that has been available for years for treatment of cryopyrin-associated periodic syndromes, has now been approved by the FDA for treatment…

Med Lett Drugs Ther. 2021 Sep 6; 63(1632):143-4
Rilonacept ( Arcalyst – Kiniksa), an interleukin-1 (IL-1) antagonist that has been available for years for treatment of cryopyrin-associated periodic syndromes, has now been approved by the FDA for treatment of recurrent pericarditis and prevention of further recurrences in patients ≥12 years old. It is the first drug to be approved in the US for this indication. Anakinra (Kineret) , an IL-1 receptor antagonist FDA-approved for treatment of rheumatoid arthritis, has been used off-label for years for treatment of recurrent pericarditis.
Issue 1621 · April 5, 2021 Free
Low-Dose Colchicine for Coronary Artery Disease

The centuries-old anti-inflammatory drug colchicine ( Colcrys , and others) is FDA-approved for prophylaxis and treatment of gout flares and for treatment of familial Mediterranean fever. It is also used…

Med Lett Drugs Ther. 2021 Apr 5; 63(1621):54-5
The centuries-old anti-inflammatory drug colchicine ( Colcrys , and others) is FDA-approved for prophylaxis and treatment of gout flares and for treatment of familial Mediterranean fever. It is also used off-label to treat pericarditis, and in recent years has been investigated for reduction of cardiovascular risk in patients with coronary artery disease (CAD).
Issue 1567 · March 11, 2019
Drugs for Gout

Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):33-7
Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.
Issue 1567 · March 11, 2019
Expanded Table: Some Drugs for Gout (online only)

View the Expanded Table: Some Drugs for Gout

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):e40-3
View the Expanded Table: Some Drugs for Gout
Issue 1485 · January 4, 2016
ColciGel - A Homeopathic Colchicine Gel for Gout

Homeopathic drugs characteristically consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated by the Roman numeral X. ColciGel (Gensco), a prescription homeopathic gel…

Med Lett Drugs Ther. 2016 Jan 4; 58(1485):5-6
Homeopathic drugs characteristically consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated by the Roman numeral X. ColciGel (Gensco), a prescription homeopathic gel containing a 10,000-fold dilution of colchicine (colchicinum 4X), is now being marketed for topical treatment and prophylaxis of gout.
Issue 1438 · March 17, 2014
Drugs for Gout

The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels.

Med Lett Drugs Ther. 2014 Mar 17; 56(1438):22-4
The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels.
Issue 1326 · November 30, 2009
Colchicine and Other Drugs for Gout

Until the recent introduction of febuxostat (Uloric) , no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now…

Med Lett Drugs Ther. 2009 Nov 30; 51(1326):93-4
Until the recent introduction of febuxostat (Uloric) , no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid ( Colbenemid , and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.
Issue 1312 · May 18, 2009
Febuxostat (Uloric) for Chronic Treatment of Gout

Febuxostat ( Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in…

Med Lett Drugs Ther. 2009 May 18; 51(1312):37-8
Febuxostat ( Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis.
Issue 1141 · October 14, 2002
Generic drugs

When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the…

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):89-90
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?